Huachuang Synthetic Pharmaceutical Co., Ltd. was founded by Shaanxi Synthetic Pharmaceutical Co., LTD., which was established in April 2009, and was restructured and changed in 2014.In March 2015, it was officially listed on the New Third Board, stock code: 832077, with a market value of about 1.2 billion yuan.The company is located in Xianxin Sixth Road, Xi 'an High-tech Zone, which is a high-tech enterprise jointly recognized by Shaanxi Provincial Science and Technology Department, Department of Finance and Tax Bureau.In December 2016, it was approved as "Shaanxi Innovative Drug Research Center".In December 2016, it was approved as "Shaanxi Innovative Drug Research Center".

The company has always been committed to the research and development of small molecule chemical innovative drugs with breakthrough effects, and has gradually formed global independent intellectual property rights.Up to now, 103 invention patents have been applied for, and 30 have been approved, including 26 domestic patents and 4 foreign patents.
       The company has a strong research and development capability, and is currently researching 14 new drugs, including 3 small molecule innovation Class 1 new drugs and 3 Class 1.1 traditional Chinese medicine innovative new drugs.In 2024, the national Class 1 new drug -Levornidazole Disodium Phosphate for Injection, the world's exclusive patented technology and the only supplier of raw materials.Due to the support of blockbuster new drugs, it is expected that the company will enter the top 100 Chinese pharmaceutical industry in 5 years.

Shaanxi Tiandirenhe Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Huachuang Synthesis. The company is located in Weinan National High-tech Development Zone, Shaanxi Province. It is a modern comprehensive drug manufacturer.The factory covers an area of about 60 mu with a registered capital of 60 million yuan.Adhering to the concept of "good raw materials, good medicine", the company strictly controls the production quality and guarantees the quality of products.
       The company has eight production lines of capsules, granules, tablets, lotions, paste, patch, Chinese medicine extraction and bulk drug in line with the GMP standards of the State Food and Drug Administration.Products include Gu yu ling jiao nang , Bei qi qi tie, Shuang zi shen xi ye, Ji sheng zhi tong gao, yin yang suo pian 5 exclusive varieties, including 15 proprietary Chinese medicine products, forming a core product group with orthopedic, gynecological and pediatric drugs as the main line.
       The company's sales network covers more than 30 provinces, municipalities and autonomous regions across the country, and has established good cooperative relations with hundreds of domestic drug circulation enterprises and more than 1,000 hospitals.